- In July 2024, AliveDx (Switzerland) introduced LumiQ, a fully automated immunofluorescence assay (IFA) solution designed for high-throughput autoimmune diagnostics, complemented by its MosaiQ planar microarray platform. This integrated "sample-to-answer" system streamlines the workflow by combining initial screening with confirmatory testing, enhancing both diagnostic speed and accuracy. It represents a significant move toward fully automated, end-to-end immunofluorescence testing in clinical labs
- In June 2023, EUROIMMUN (Revvity, Inc.) launched the UNIQO 160, an advanced automated indirect immunofluorescence testing (IIFT) system. Designed to handle up to 160 samples per run, it integrates sample preparation, incubation, washing, slide mounting, image acquisition, and analysis into a single benchtop unit—reducing hands-on time and streamlining workflows
- In June 2023, EUROIMMUN expanded compatibility for its EUROPattern Microscope Live, enabling 89 new IIFT assays covering vasculitis, hepatology, gastroenterology, neurology, endocrinology, nephrology, and dermatology. The update triples the system's throughput and diagnostic coverage
- In May 2023, Thermo Fisher Scientific introduced a new Autoimmune Assay Kit, engineered to deliver faster and more accurate detection of autoantibodies across a spectrum of conditions. This offering underscores Thermo Fisher’s investment in precision diagnostics for autoimmune disorders
- In March 2023, Trinity Biotech rolled out the Autoimmune Panel Plus, a diagnostic multiplex assay designed to streamline laboratory workflows by enabling simultaneous detection of multiple autoantibodies, thereby enhancing diagnostic efficiency and throughput
